RVNC (Revance Therapeutics) Short-Term Debt to Capital

Corporate company logo of Revance Therapeutics (RVNC)

Due to grueling dumping in the aesthetics niche, Revance Therapeutics (RVNC) was forced to merge with another player to preserve its brand. Fierce competition with industry behemoths possessing colossal advertising budgets created serious risks. The company is currently developing a closed B2B environment around Daxxify to retain clinics within its network. The asset value of 0.00 shown on this chart reflects the current financial state of this business.

Ratio of Short-Term Indebtedness to Capital: Revance Therapeutics, Inc (RVNC) for 07/04/2022 - 02/16/2025

Analytical breakdowns for Revance Therapeutics

- stock quotes and analyst forecast:
Stock Price Revance Therapeutics, Inc|RVNC - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Revance Therapeutics Inc.|RVNC - Enterprise Value
- book capitalization information:
Net Assets per Single Share Revance Therapeutics|RVNC - Accounting Value of Company|Market Value to Book Value Ratio revance.com|RVNC - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Revance Therapeutics|RVNC - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Revance Therapeutics, Inc.|RVNC - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Revance Therapeutics Inc.|RVNC - Long-Term Debt Volume|Company Short-Term Debt Revance Therapeutics|Quick Ratio revance.com
- company profitability and valuation multiples indicators:
RVNC - Net Financial Result
Fundamental valuation:RVNC Revance Therapeutics, Inc
Brand item of Revance Therapeutics Inc.

This indicator assesses financial stability through the ratio of liabilities maturing within one year to equity, where the short-term debt-to-equity ratio visualizes the company's reliance on operational borrowing. For the biopharmaceutical business of Revance Therapeutics (RVNC), which operates under strict FDA regulations, such a financing structure is critical to ensuring the current utilization of biomaterials without risking a loss of solvency.

Main competitors

Short-Term Debt to Capital KRYS|APGE (Apogee Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ARQT (Arcutis Biotherapeutics)|Short-Term Debt to Capital vcel.com VCEL|ORKA - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital SMTI (Sanara MedTech Inc.)|dbv-technologies.com (DBVT) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Solesence|DERM (Journey Medical Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital fortebiorx.com|Short-Term Debt to Equity Ratio EMPG (Empro Group)|SLGL (Sol-Gel Technologies Ltd) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity AXIL Brands AXIL|Short-Term Debt to Capital Coefficient Medicus Pharma Corp (MDCX)|VRCA - Short-Term Debt to Equity|HOTH - Short-Term Debt to Capital|BFRI: Short-Term Debt to Capital|VYNE - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Sonoma Pharmaceuticals Inc.|Short-Term Debt to Capital Ratio QNRX (Quoin Pharma)|Short-Term Debt to Equity Azitra, Inc. (AZTR)|DRMA (dermatarx.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ELAB (Elevai Labs)